JDJosefine Winther Davy

Josefine Winther Davy

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Josefine Winther Davy has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Marianne Melau

    Bispebjerg and Frederiksberg Hospital, Mental Health Services, Copenhagen, Denmark

    3 shared publications
  • Merete Nordentoft

    Copenhagen Research Centre for Mental Health—CORE, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

    3 shared publications
  • Benjamin Thorup Arnfred

    Copenhagen Research Centre for Mental Health—CORE, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

    2 shared publications
  • Carsten Hjorthøj

    Copenhagen Research Centre for Mental Health—CORE, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

    2 shared publications
  • Lene Qvist Larsen

    CORE‐Copenhagen Research Center for Mental Health, Mental Health Services in the Capital Region, Department of Clinical Medicine, Faculty of Health Sciences University of Copenhagen Copenhagen Denmark

    2 shared publications
  • Anne Bryde Christensen

    Center for Eating and Feeding Disorders Research, Mental Health Center Ballerup, Copenhagen University Hospital – Mental Health Services CPH, Copenhagen, Denmark

    1 shared publication

Latest Publications

  • Open Access

    The Price and Prize for Employment or Education: a Qualitative Study Examining Facilitators and Barriers from the Perspectives of Service Providers working in Supported Employment and Education and Experts by Experience with Psychosis Spectrum Disorders

    by Josefine Winther Davy, Benjamin Thorup Arnfred, Carsten Hjorthøj, Julie Midtgaard, Merete Nordentoft, Marianne Melau

    Purpose: Many with psychosis spectrum disorders are not in education, employment, or training. The present study aimed to describe the facilitators and barriers surrounding competitive employment or advanced education. Methods: Qualitative data were collected through first three interviews with service providers working in SEE ( N = 3), followed by two focus groups with experts by experience with schizophrenia spectrum disorders ( N = 13). The interviews and focus group discussions were audio taped and transcribed, enabling reflexive thematic analysis. Results: Three themes, each compromising two subthemes, were identified. The participants described the (1) Price and prize of work and study, including (1.1) Breaking points and (1.2) Motivations. In (2) Facilitators: The importance of individualized support, interventions were viewed as either (2.1) Fruitful or (2.2) Futile. The participants described (3) Barriers: Managing the invisible in conjunction with (3.1.) Symptoms and (3.2) Handling stigma. Conclusion: Experts by experience with psychosis spectrum disorders are highly motivated to pursue education or employment. Both benefits and challenges of this were identified. While work or study was seen as meaningful and confidence-building, it could also worsen symptoms or trigger first episode psychosis. Professionals taking a special interest in job-seeking were valued, though factors like lacking social skills and stigma formed barriers. Overall, the findings highlight strong motivation alongside a need for flexible, individualized approaches that balance opportunities with mental health risks.

  • Open Access

    Stigma experienced as worse than symptoms of schizophrenia: A qualitative study about The OpusPanel

    by Josefine Winther Davy, Benjamin Thorup Arnfred, Lene Qvist Larsen, Freja Pagels Christensen, Tina Iversen, Lene Falgaard Eplov, Merete Nordentoft, Marianne Melau

    Aim: Former patients and relatives of people who have received treatment in OPUS, a Danish specialized early intervention for first episode psychosis, have since 2009 worked to reduce stigma and increase hope related to schizophrenia and psychosis. They established The OpusPanel to share their own stories of living with an invisible disorder with new patients, health care professionals, politicians, and members of the public. The impact of The OpusPanel on stigma has not previously been explored or evaluated. The article aims to evaluate and gain an in‐depth understanding of The OpusPanel's anti‐stigma impact.Methods: In a qualitative design, 27 people with different affiliations to The OpusPanel were interviewed using semi‐structured interview guides to capture their individual experiences of listening to, interacting with, or being part of The OpusPanel. Interview guides were constructed following a focus group interview with members of The OpusPanel. Analysis of the multi‐perspectival dataset was facilitated through an interpretative phenomenological approach with investigator triangulation. Preliminary results were returned to the focus group members to ensure relevance and accuracy.Results: The study found that almost all interviewees described a sense of hopefulness and decreased stigma after having experienced a member from The OpusPanel present their story or participating as panel members themselves.Conclusion: The findings suggest that attending presentations or participating in The OpusPanel reduces stigmatizing views about others or oneself. The study may inform The OpusPanel and similar initiatives for challenging stigma related to schizophrenia or psychosis.


  • Open Access

    Self‐reported reasons for discontinuation or continuation of antipsychotic medication in individuals with first‐episode schizophrenia

    by Anne Emilie Stürup, Carsten Hjorthøj, Heidi Dorthe Jensen, Marianne Melau, Josefine Winther Davy, Merete Nordentoft, Nikolai Albert

    Aim: Many individuals with schizophrenia discontinue initially prescribed antipsychotics. Knowledge on reasons for discontinuation among individuals with first‐episode schizophrenia is sparse. We aimed to describe reasons for discontinuation and continuation, differences between individuals discontinuing and continuing, and factors predicting reasons for discontinuation or continuation.Methods: This was a prospective cohort study with a post hoc design. Individuals with first‐episode schizophrenia were included from early intervention teams in Denmark from 2009–2012. Sociodemographic and clinical variables were collected at baseline and reasons for discontinuation and continuation of antipsychotics were assessed at 3.5‐year follow‐up.Results: Among 215 patients, 76 reported reasons for discontinuation and 139 for continuation. The most frequent reasons for discontinuation were “side effects” and “patient believed he/she no longer needed the medication because he/she was now better”. The most frequent reasons for continuation were “benefits for positive symptoms” and “another person told them to”. Individuals who discontinued antipsychotics were at baseline younger, had longer DUP, less negative symptoms, better social function, lower compliance, higher self‐belief of coping, and fewer used antipsychotics compared to those continuing antipsychotics.Conclusions: The effect of antipsychotics is the main reason to continue, whereas side effects were the main reason to discontinue. Knowledge of reasons to discontinue or continue is helpful in shared decision‐making, identifying individuals with high odds of discontinuation, improving adherence, and helping with safe discontinuation.